Checkpoint Capital L.P.
CIK 1977548 · View on SEC EDGAR ↗
- Portfolio value
- $389.8M
- Positions
- 6
- As of
- June 30, 2026
Portfolio value QoQ: +39.9% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 5
- Effective number of positions
- 3.8
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 9.57% Est. buys $53,279,906 · sells $31,997,823
Median holding: 2.0 quarters Tracked Q4 2024–Q2 2026 · 26.1% still held
- New positions
- 0
- Increased
- 3
- Decreased
- 3
- Closed
- 2
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +50.6% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.3%
Sector breakdown
Full portfolio 6 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals, Inc. - Common Stock | $131,681,580 | 33.79% | 1,186,000 | $24,951,996 | Down ×1 | ||
| ARGX argenx SE - American Depositary Shares | $121,800,429 | 31.25% | 131,283 | $10,072,179 | Down ×1 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $76,850,910 | 19.72% | 410,353 | $51,318,992 | Up ×1 | ||
| CYTK Cytokinetics, Incorporated - Common Stock | $40,465,250 | 10.38% | 475,000 | $28,601,450 | Up ×3 | ||
| IRON Disc Medicine, Inc. - Common Stock | $17,562,743 | 4.51% | 240,125 | $-766,361 | Down ×2 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $1,398,750 | 0.36% | 75,000 | $802,250 | Up ×1 | ||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
| Security | Value | % of portfolio | Streak |
|---|---|---|---|
| CYTK | $40,465,250 | 10.38% | up ×3 |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| PHAT | March 31, 2025 | 2,274,157 | $18,466,155 | 54.2% |
| CORT | March 31, 2026 | 529,695 | $18,433,386 | 197.7% |
| AXSM | March 31, 2025 | 174,769 | $14,787,205 | 88.9% |
| SLNO | June 30, 2025 | 172,902 | $12,353,848 | No longer tracked |
| CRNX | Dec. 31, 2025 | 260,000 | $10,829,000 | 82.1% |
| AVDL | March 31, 2025 | 1,004,790 | $10,560,343 | No longer tracked |
| PLRX | March 31, 2025 | 535,494 | $7,052,456 | -12.2% |
| SEPN | Dec. 31, 2025 | 283,158 | $5,326,202 | 57.9% |
| STOK | Dec. 31, 2025 | 212,049 | $4,983,152 | 4.6% |
| STOK | June 30, 2025 | 730,717 | $4,859,268 | 192.4% |
| PTGX | Sept. 30, 2025 | 81,311 | $4,494,059 | 137.4% |
| TRVI | March 31, 2025 | 1,084,135 | $4,466,636 | 199.4% |
| KYMR | Dec. 31, 2025 | 61,750 | $3,495,050 | 59.5% |
| TCRX | June 30, 2025 | 2,017,650 | $2,784,357 | -44.8% |
| SEPN | June 30, 2026 | 100,300 | $2,410,209 | 31.4% |
| CDTX | June 30, 2025 | 104,380 | $2,248,345 | No longer tracked |
| ATYR | March 31, 2025 | 432,561 | $1,565,871 | -82.5% |
| CRNX | June 30, 2026 | 40,230 | $1,461,154 | 126.5% |
| CYTK | March 31, 2025 | 20,000 | $940,800 | 90.8% |
| IMCR | June 30, 2025 | 9,011 | $267,356 | 16.9% |
| RAPT | June 30, 2025 | 109,830 | $133,993 | No longer tracked |